MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Positions Curium as leading manufacturer of Lu-177 isotope
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
Harnessing advanced data analysis for early detection, prevention and better outcomes
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Subscribe To Our Newsletter & Stay Updated
